Press Resease

Recombinant Vaccines Market - Global Industry Analysis

Recombinant Vaccines Market By Product (Attenuated, Vector, and Subunit), By Application (Veterinary and Human), By Disease (Hepatitis B, Cancer, Influenza, and Others), and By Distribution Channel (Hospitals, Clinics, Veterinary Clinics, Retail Pharmacies, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 11-Oct-2019 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-4836 Status : Published

Global recombinant vaccines market expected to generate around USD 1,685 million by 2025, at a CAGR of around 6.5% between 2019 and 2025. Recombinant DNA molecules are prepared by genetic recombination methods to link genetic material from various sources.

Description

The report covers a forecast and an analysis of the recombinant vaccines market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints of the recombinant vaccines market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the recombinant vaccines market on a global and regional level.

In order to give the users a comprehensive view of the recombinant vaccines market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Recombinant Vaccines Market

The report provides company market share analysis to give a broader overview of the key players in the recombinant vaccines market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the recombinant vaccines market on a global and regional basis.

The study provides a decisive view of the recombinant vaccines market by segmenting the market based on type, application, disease, distribution channel, and region. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Some key players of the global recombinant vaccines market are Pfizer, Merck, Sanofi Pasteur, Bayer, GlaxoSmithKline, Serum Institute of India, Abiomed, Johnson & Johnson, Emergent Bio Solutions, and Mitsubishi Tanabe Pharma.

This report segments the global recombinant vaccines market as follows:

Global Recombinant Vaccines Market: By Type

  • Attenuated
  • Vector
  • Subunit

Global Recombinant Vaccines Market: By Application

  • Veterinary
  • Human

Global Recombinant Vaccines Market: By Disease

  • Hepatitis B
  • Cancer
  • Influenza
  • Others

Global Recombinant Vaccines Market: By Distribution Channel

  • Hospitals
  • Clinics
  • Veterinary Clinics
  • Retail Pharmacies
  • Others

Global Recombinant Vaccines Market: By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Recombinant Vaccines Market, 2016-2025 (USD Million)
    • 2.2. Global Recombinant Vaccines Market: Snapshot
  •  
  • Chapter 3. Recombinant Vaccines Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Safe to use nature of recombinant vaccines
      • 3.2.2. High investment by recombinant vaccine manufacturers for the development of novel products
    • 3.3. Market restraints
      • 3.3.1. Risk related to the use of attenuated vaccines
      • 3.3.2. The high cost of recombinant vaccines
    • 3.4. Opportunities
      • 3.4.1. Rising awareness regarding recombinant vaccines benefits in developing regions
      • 3.4.2. Rising per capita healthcare expenditure
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Type
      • 3.6.2. Market attractiveness analysis, by Application
      • 3.6.3. Market attractiveness analysis, by Disease
      • 3.6.4. Market attractiveness analysis, by Distribution Channel
      • 3.6.5. Market attractiveness analysis, by Region
  •  
  • Chapter 4. Global Recombinant Vaccines Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Recombinant Vaccines market: company Market Share, 2019
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations, and Joint Ventures
      • 4.2.4. Research and Development and Regional Expansion
  •  
  • Chapter 5. Global Recombinant Vaccines Market - Type Analysis
    • 5.1. Global Recombinant Vaccines Market: Type overview
      • 5.1.1. Global Recombinant Vaccines Market Share, by Type, 2018 and 2025
    • 5.2. Attenuated
      • 5.2.1. Global Recombinant Vaccines Market for Attenuated, 2016-2025 (USD Million)
    • 5.3. Vector
      • 5.3.1. Global Recombinant Vaccines Market for Vector, 2016-2025 (USD Million)
    • 5.4. Subunit
      • 5.4.1. Global Recombinant Vaccines Market for Subunit, 2016-2025 (USD Million)
  •  
  • Chapter 6. Global Recombinant Vaccines Market - Application Analysis
    • 6.1. Global Recombinant Vaccines Market: Application overview
      • 6.1.1. Global Recombinant Vaccines Market Share, by Application, 2018 and 2025
    • 6.2. Veterinary
      • 6.2.1. Global Recombinant Vaccines Market for Veterinary, 2016-2025 (USD Million)
    • 6.3. Human
      • 6.3.1. Global Recombinant Vaccines Market for Human, 2016-2025 (USD Million)
  •  
  • Chapter 7. Global Recombinant Vaccines Market - Disease Analysis
    • 7.1. Global Recombinant Vaccines Market: Disease overview
      • 7.1.1. Global Recombinant Vaccines Market Share, by Disease, 2018 and 2025
    • 7.2. Hepatitis B
      • 7.2.1. Global Recombinant Vaccines Market for Hepatitis B, 2016-2025 (USD Million)
    • 7.3. Cancer
      • 7.3.1. Global Recombinant Vaccines Market for Cancer, 2016-2025 (USD Million)
    • 7.4. Influenza
      • 7.4.1. Global Recombinant Vaccines Market for Influenza, 2016-2025 (USD Million)
    • 7.5. Others
      • 7.5.1. Global Recombinant Vaccines Market for Others, 2016-2025 (USD Million)
  •  
  • Chapter 8. Global Recombinant Vaccines Market - Distribution Channel Analysis
    • 8.1. Global Recombinant Vaccines Market: Distribution Channel overview
      • 8.1.1. Global Recombinant Vaccines Market Share, by Distribution Channel, 2018 and 2025
    • 8.2. Hospitals
      • 8.2.1. Global Recombinant Vaccines Market for Hospitals, 2016-2025 (USD Million)
    • 8.3. Clinics
      • 8.3.1. Global Recombinant Vaccines Market for Clinics, 2016-2025 (USD Million)
    • 8.4. Veterinary Clinics
      • 8.4.1. Global Recombinant Vaccines Market for Veterinary Clinics, 2016-2025 (USD Million)
    • 8.5. Retail Pharmacies
      • 8.5.1. Global Recombinant Vaccines Market for Retail Pharmacies, 2016-2025 (USD Million)
    • 8.6. Others
      • 8.6.1. Global Recombinant Vaccines Market for Others, 2016-2025 (USD Million)
  •  
  • Chapter 9. Global Recombinant Vaccines Market - Regional Analysis
    • 9.1. Global Recombinant Vaccines Market: Regional overview
      • 9.1.1. Global Recombinant Vaccines Market Share, by region, 2018 and 2025
    • 9.2. North America
      • 9.2.1. North America Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
      • 9.2.2. North America Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
      • 9.2.3. North America Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
      • 9.2.4. North America Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 9.2.5. The U.S.
        • 9.2.5.1. The U.S. Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
        • 9.2.5.2. The U.S. Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
        • 9.2.5.3. The U.S. Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
        • 9.2.5.4. The U.S. Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 9.2.6. Rest of North America
        • 9.2.6.1. Rest of North America Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
        • 9.2.6.2. Rest of North America Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
        • 9.2.6.3. Rest of North America Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
        • 9.2.6.4. Rest of North America Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
    • 9.3. Europe
      • 9.3.1. Europe Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
      • 9.3.2. Europe Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
      • 9.3.3. Europe Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
      • 9.3.4. Europe Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 9.3.5. Germany
        • 9.3.5.1. Germany Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
        • 9.3.5.2. Germany Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
        • 9.3.5.3. Germany Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
        • 9.3.5.4. Germany Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 9.3.6. The U.K.
        • 9.3.6.1. U.K. Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
        • 9.3.6.2. U.K. Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
        • 9.3.6.3. U.K. Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
        • 9.3.6.4. U.K. Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 9.3.7. France
        • 9.3.7.1. France Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
        • 9.3.7.2. France Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
        • 9.3.7.3. France Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
        • 9.3.7.4. France Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 9.3.8. Rest of Europe
        • 9.3.8.1. Rest of Europe Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
        • 9.3.8.2. Rest of Europe Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
        • 9.3.8.3. Rest of Europe Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
        • 9.3.8.4. Rest of Europe Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
      • 9.4.2. Asia Pacific Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
      • 9.4.3. Asia Pacific Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
      • 9.4.4. Asia Pacific Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 9.4.5. China
        • 9.4.5.1. China Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
        • 9.4.5.2. China Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
        • 9.4.5.3. China Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
        • 9.4.5.4. China Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 9.4.6. Japan
        • 9.4.6.1. Japan Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
        • 9.4.6.2. Japan Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
        • 9.4.6.3. Japan Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
        • 9.4.6.4. Japan Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 9.4.7. India
        • 9.4.7.1. India Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
        • 9.4.7.2. India Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
        • 9.4.7.3. India Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
        • 9.4.7.4. India Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 9.4.8. Rest of Asia Pacific
        • 9.4.8.1. Rest of Asia Pacific Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
        • 9.4.8.2. Rest of Asia Pacific Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
        • 9.4.8.3. Rest of Asia Pacific Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
        • 9.4.8.4. Rest of Asia Pacific Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
    • 9.5. Latin America
      • 9.5.1. Latin America Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
      • 9.5.2. Latin America Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
      • 9.5.3. Latin America Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
      • 9.5.4. Latin America Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 9.5.5. Brazil
        • 9.5.5.1. Brazil Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
        • 9.5.5.2. Brazil Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
        • 9.5.5.3. Brazil Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
        • 9.5.5.4. Brazil Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 9.5.6. Rest of Latin America
        • 9.5.6.1. Rest of Latin America Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
        • 9.5.6.2. Rest of Latin America Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
        • 9.5.6.3. Rest of Latin America Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
        • 9.5.6.4. Rest of Latin America Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
    • 9.6. The Middle East and Africa
      • 9.6.1. The Middle East and Africa Recombinant Vaccines Market Revenue, by Type, 2016-2025 (USD Million)
      • 9.6.2. The Middle East and Africa Recombinant Vaccines Market Revenue, by Application, 2016-2025 (USD Million)
      • 9.6.3. The Middle East and Africa Recombinant Vaccines Market Revenue, by Disease, 2016-2025 (USD Million)
      • 9.6.4. The Middle East and Africa Recombinant Vaccines Market Revenue, by Distribution Channel, 2016-2025 (USD Million)
  •  
  • Chapter 10. Company Profile
    • 10.1. Pfizer
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Disease portfolio
      • 10.1.4. Business strategy
      • 10.1.5. Recent developments
    • 10.2. Merck
      • 10.2.1. Overview
      • 10.2.2. Financials
      • 10.2.3. Disease portfolio
      • 10.2.4. Business strategy
      • 10.2.5. Recent developments
    • 10.3. Sanofi Pasteur
      • 10.3.1. Overview
      • 10.3.2. Financials
      • 10.3.3. Disease portfolio
      • 10.3.4. Business strategy
      • 10.3.5. Recent developments
    • 10.4. Bayer
      • 10.4.1. Overview
      • 10.4.2. Financials
      • 10.4.3. Disease portfolio
      • 10.4.4. Business strategy
      • 10.4.5. Recent developments
    • 10.5. GlaxoSmithKline
      • 10.5.1. Overview
      • 10.5.2. Financials
      • 10.5.3. Disease portfolio
      • 10.5.4. Business strategy
      • 10.5.5. Recent developments
    • 10.6. Serum Institute of India
      • 10.6.1. Overview
      • 10.6.2. Financials
      • 10.6.3. Disease portfolio
      • 10.6.4. Business strategy
      • 10.6.5. Recent developments
    • 10.7. Abiomed
      • 10.7.1. Overview
      • 10.7.2. Financials
      • 10.7.3. Disease portfolio
      • 10.7.4. Business strategy
      • 10.7.5. Recent developments
    • 10.8. Johnson & Johnson
      • 10.8.1. Overview
      • 10.8.2. Financials
      • 10.8.3. Disease portfolio
      • 10.8.4. Business strategy
      • 10.8.5. Recent developments
    • 10.9. Emergent Bio Solutions
      • 10.9.1. Overview
      • 10.9.2. Financials
      • 10.9.3. Disease portfolio
      • 10.9.4. Business strategy
      • 10.9.5. Recent developments
    • 10.10. Mitsubishi Tanabe Pharma
      • 10.10.1. Overview
      • 10.10.2. Financials
      • 10.10.3. Disease portfolio
      • 10.10.4. Business strategy
      • 10.10.5. Recent developments

List of Figures

1. Market research process
2. Market research methodology
3. Global Recombinant Vaccines Market Revenue, 2016–2025 (USD Million) 
4. Porter’s Five Forces Analysis
5. Recombinant Vaccines Market attractiveness analysis, by Type
6. Recombinant Vaccines Market attractiveness analysis, by Application
7. Recombinant Vaccines Market attractiveness analysis, by Disease segment
8. Recombinant Vaccines Market attractiveness analysis, by Distribution Channel
9. Recombinant Vaccines: Market attractiveness analysis, by Region
10. Company market share analysis, 2018
11. Global Recombinant Vaccines Market Share by Type, 2018 and 2025
12. Global Recombinant Vaccines Market for Attenuated, 2016–2025 (USD Million)
13. Global Recombinant Vaccines Market for Vector, 2016–2025 (USD Million)
14. Global Recombinant Vaccines Market for Subunit, 2016–2025 (USD Million)
15. Global Recombinant Vaccines Market Share by Application, 2018 and 2025
16. Global Recombinant Vaccines Market for Veterinary, 2016–2025 (USD Million)
17. Global Recombinant Vaccines Market for Human, 2016–2025 (USD Million)
18. Global Recombinant Vaccines Market Share by Disease, 2018 and 2025
19. Global Recombinant Vaccines Market for Hepatitis B, 2016–2025 (USD Million)
20. Global Recombinant Vaccines Market for Cancer, 2016–2025 (USD Million)
21. Global Recombinant Vaccines Market for Influenza, 2016–2025 (USD Million)
22. Global Recombinant Vaccines Market for Others, 2016–2025 (USD Million)
23. Global Recombinant Vaccines Market for Distribution Channel, 2016–2025 (USD Million)
24. Global Recombinant Vaccines Market for Hospitals, 2016–2025 (USD Million)
25. Global Recombinant Vaccines Market for Clinics, 2016–2025 (USD Million)
26. Global Recombinant Vaccines Market for Veterinary Clinics, 2016–2025 (USD Million)
27. Global Recombinant Vaccines Market for Retail Pharmacies, 2016–2025 (USD Million)
28. Global Recombinant Vaccines Market for Others, 2016–2025 (USD Million)
29. North America Recombinant Vaccines Market, 2016–2025 (USD Million)
30. Europe Recombinant Vaccines market, 2016–2025 (USD Million)
31. Asia Pacific Recombinant Vaccines Market, 2016–2025 (USD Million)
32. Latin America Recombinant Vaccines Market, 2016–2025 (USD Million)
33. The Middle East and Africa Recombinant Vaccines Market, 2016–2025 (USD Million)


List of Tables

1. Recombinant Vaccines Market: Snapshot
2. Drivers of the global Recombinant Vaccines Market: Impact analysis
3. Restraints of the global Recombinant Vaccines Market: Impact analysis
4. North America Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
5. North America Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
6. North America Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
7. North America Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)
8. The U.S. Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
9. The U.S. Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
10. The U.S. Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
11. The U.S. Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)
12. Rest of North America Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
13. Rest of North America Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
14. Rest of North America Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
15. Rest of North America Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)
16. Europe Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
17. Europe Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
18. Europe Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
19. Europe Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)
20. Germany Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
21. Germany Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
22. Germany Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
23. Germany Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)
24. U.K. Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
25. U.K. Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
26. U.K. Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
27. U.K. Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)
28. France Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
29. France Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
30. France Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
31. France Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)
32. Rest of Europe Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
33. Rest of Europe Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
34. Rest of Europe Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
35. Rest of Europe Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)
36. Asia Pacific Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
37. Asia Pacific Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
38. Asia Pacific Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
39. Asia Pacific Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)
40. China Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
41. China Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
42. China Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
43. China Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)
44. Japan Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
45. Japan Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
46. Japan Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
47. Japan Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)
48. India Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
49. India Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
50. India Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
51. India Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)
52. Rest of Asia Pacific Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
53. Rest of Asia Pacific Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
54. Rest of Asia Pacific Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
55. Rest of Asia Pacific Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)
56. Latin America Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
57. Latin America Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
58. Latin America Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
59. Latin America Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)
60. Brazil Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
61. Brazil Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
62. Brazil Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
63. Brazil Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)
64. Rest of Latin America Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
65. Rest of Latin America Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
66. Rest of Latin America Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
67. Rest of Latin America Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)
68. The Middle East and Africa Recombinant Vaccines Market Revenue, by Type, 2016–2025 (USD Million)
69. The Middle East and Africa Recombinant Vaccines Market Revenue, by Application, 2016–2025 (USD Million)
70. The Middle East and Africa Recombinant Vaccines Market Revenue, by Disease, 2016–2025 (USD Million)
71. The Middle East and Africa Recombinant Vaccines Market Revenue, by Distribution Channel, 2016–2025 (USD Million)

Methodology

Free Analysis

A vaccine is a biological product that offers active attained immunity against a specific disease. A recombinant vaccine is manufactured via recombinant DNA (rDNA) technology. This includes introducing the DNA (Deoxyribonucleic Acid) encoding an antigen, which encourages an immune reaction into mammalian or bacterial cells, by articulating the antigen in these cells and then refining it from them.

The safe to use nature of recombinant vaccines, high investments by recombinant vaccine manufacturers for novel products’ development, rising government initiatives to boost the recombinant vaccines usage, increasing augmented and viable healthcare demand, simplified applications of recombinant vaccines, and growing accessibility of recombinant vaccines via conventional supply chains, escalating number of regulatory authorizations, and growing infectious diseases occurrence are driving the recombinant vaccines market globally. The rising awareness regarding recombinant vaccines benefits in developing regions, increasing per capita healthcare expenditure, growing demand for veterinary recombinant vaccines, and ongoing technological improvements in recombinant vaccines will create additional opportunities for the recombinant vaccines market in the years ahead. However, risks related to the use of attenuated vaccines, high cost of recombinant vaccines, and the lack of appropriate healthcare setup and trained physicians in developing regions will restrict the global recombinant vaccines market development.

Global Recombinant Vaccines Market

The recombinant vaccines market is split based on type, application, disease, and distribution channel. Based on type, the recombinant vaccines market includes attenuated, vector, and subunit. The subunit segment accounted for the highest market share in 2018. The application segment includes veterinary and human. The human segment accounted for the highest market share in 2018. The disease segment comprises hepatitis B, cancer, influenza, and others. The hepatitis B segment is expected to register the highest CAGR over the estimated time period. The distribution channel segment is fragmented into hospitals, clinics, veterinary clinics, retail pharmacies, and others.

North America will lead the global recombinant vaccines market in the future, owing to rising developments in the field of genetic engineering and molecular biology, increasing transmittable diseases prevalence, huge research and development expenditure by major manufacturers, high vaccination rate, and rapid uptake of techniques like rDNA technology. Europe will hold the second spot in this global market, due to the presence of latest treatment facilities, high healthcare expenditure, rising infectious disorders incidences, escalating cancer rate, and growing availability of latest healthcare infrastructure. The Asia Pacific will grow rapidly over the forecast period, owing to the rising government initiatives governments to increase vaccination rate, an enormous patient pool, increasing investments by domestic and global manufacturers, escalating need for large quantities of vaccines, and ongoing R&D.

Some key players of the global recombinant vaccines market are Pfizer, Merck, Sanofi Pasteur, Bayer, GlaxoSmithKline, Serum Institute of India, Abiomed, Johnson & Johnson, Emergent Bio Solutions, and Mitsubishi Tanabe Pharma.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed